Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VXRT 11.19.2024

Full Press ReleaseSEC FilingsOur VXRT Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
  • 01.14.2025 - Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
  • 12.02.2024 - Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Recent Filings

  • 01.21.2025 - EX-99.1 EX-99.1
  • 01.21.2025 - 8-K Current report
  • 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

SOUTH SAN FRANCISCO, Calif.,Nov. 19, 2024(GLOBE NEWSWIRE) --Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that onNovember 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its common stock to two new non-executive employees to induce them to accept employment withVaxart.

The awards consisted of stock options to purchase an aggregate of 61,000 shares of Vaxart’s common stock, which vest as to 1/4th of the total shares on the one-year anniversary of the grant date, and as to 1/48th of the total shares on each month thereafter, and have a per share exercise price equal to the closing price of Vaxart’s common stock on the grant date; and restricted stock unit awards covering an aggregate of 30,500 shares of Vaxart’s common stock, which vest as to 25% of the shares underlying the awards on the first, second, third and fourth anniversary of the grant date.

The awards were granted under theVaxart, Inc.2024 Inducement Award Plan as an employment “inducement award” pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees ofVaxart(or following a bona fide period of non-employment) as an inducement material to entering into employment withVaxart.

AboutVaxart

Vaxartis a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.Vaxartvaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury.Vaxartbelieves that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication.Vaxarthas filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor Relations:Matt SteinbergFINN PartnersIR@vaxart.com(646) 871-8481

This press release was published by a CLEAR® Verified individual.

Primary Logo

Source: Vaxart, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com